Intelligence Profile
Clinical Applications
Colipral is being investigated for several potential clinical applications, based on preliminary evidence from clinical trials. Here's a summary of its evaluated uses:
Prevention of Recurrent Cystitis in Menopausal Women: The trial titled "Colipral® (Probiotic Strain Escherichia Coli 5C (ECP24®)) for Prevention of Recurrent Cystitis in Menopausal Women" aims to assess the effectiveness of Colipral in preventing recurrent bladder infections, particularly in menopausal women. As of now, the research has not yet commenced (status: NOT_YET_RECRUITING), so no findings are available at this time.
Ulcerative Colitis During Remission: Another ongoing investigation, "Evaluation of the Effects of Colipral on Microbiota Gut Composition in Patients Presenting With Ulcerative Colitis During Remission Phase and Functional Disorders," plans to explore how Colipral impacts gut microbiota composition in patients with ulcerative colitis. This study is also in the preliminary stages (status: NOT_YET_RECRUITING), and results have not been published.
Post-Colonoscopy Gastrointestinal Symptoms: The study "Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms" intends to evaluate Colipral's effect on gastrointestinal symptoms following a colonoscopy. Like the others, this trial is still in the planning phase (status: NOT_YET_RECRUITING), leaving the outcomes to be determined.
At this point, clinical applications of Colipral are largely hypothetical, pending results from these pending trials. Further evidence is required to substantiate its efficacy and safety for these conditions.
Disclaimer: This is not personalized medical advice. Consult with a healthcare provider for advice tailored to individual health needs.